ArticleEngineering in life sciences2022
Stress-induced increase of monoclonal antibody production in CHO cells.
Article in Engineering in life sciences, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 20 citations in OpenAlex.
- Data-Driven Approach for Bioreactor Monitoring and Prediction in Monoclonal Antibody Production.ACS omega · 2026Article
- 3D-bioprinted microenvironments shape the growth and IgG1 monoclonal antibody production of CHO DG44 cells.Frontiers in bioengineering and biotechnology · 2026Article
- A Fed-batch Process for the Production of Recombinant Adeno-associated Virus (rAAV) Vectors Using the Sf9-Rhabdovirus-negative Cell Line.Current pharmaceutical biotechnology · 2026Article
- MemorySeq identifies heritable epigenetic phenotypes that initiate cell culture stress tolerance in CHO cells.iScience · 2025Article
- Antibody Aggregate Removal by Multimodal Chromatography.Molecules (Basel, Switzerland) · 2025Review
- Machine Learning-Powered Optimization of a CHO Cell Cultivation Process.Biotechnology and bioengineering · 2025Article
- Optimization of the intron sequences combined with the CMV promoter increases recombinant protein expression in CHO cells.Scientific reports · 2025Article
- Characterization of the Ubiquitin-Modified Proteome of Recombinant Chinese Hamster Ovary Cells in Response to Endoplasmic Reticulum Stress.Biotechnology journal · 2024Article
- Establishment of a Perfusion Process with Antibody-Producing CHO Cells Using a 3D-Printed Microfluidic Spiral Separator with Web-Based Flow Control.Bioengineering (Basel, Switzerland) · 2023Article
- Progress in fed-batch culture for recombinant protein production in CHO cells.Applied microbiology and biotechnology · 2023Review
- Stress-induced increase of monoclonal antibody production in CHO cells.Engineering in life sciences · 2022Article
- Improving outcomes in intensified processing via optimization of the cell line development workflow.Biotechnology progressArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Monoclonal antibodies (mAbs) are of great interest to the biopharmaceutical industry due to their widely used application as human therapeutic and diagnostic agents. As such, mAb require to exhibit human-like glycolization patterns. Therefore, recombinant Chinese hamster ovary (CHO) cells are the favored production organisms; many relevant biopharmaceuticals are already produced by this cell type. To optimize the mAb yield in CHO DG44 cells a corelation between stress-induced cell size expansion and increased specific productivity was investigated. CO
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.